Vimarsana
Biggest News Aggregation in the World

Approved Indication News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Approved Indication. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Approved Indication Today - Breaking & Trending Today

Eli Lilly warns against 'cosmetic' use of popular diabetes, obesity drugs - Vimarsana News

Eli Lilly warns against 'cosmetic' use of popular diabetes, obesity drugs

Drugmaker Eli Lilly on Thursday warned against using its diabetes and obesity drugs for “cosmetic” weight loss, as the medications have exploded in popularity, resulting in shortages. In an open letter posted online, the company said its products Mounjaro and Zepbound “are indicated for the treatment of serious diseases; they are not approved for —…

Source: yahoo.com
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma - Vimarsana News

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma

Study met primary and key secondary endpoints, demonstrating a highly statistically significant improvement in event-free survival, complete response rate and progression-free survival compared to standard of care Breyanzi safety results consistent with data from pivotal TRANSCEND NHL 001 trial Results represent the first time a therapy has demonstrated benefit compared to high-dose chemotherapy and stem cell ...

New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo's Continued Commitment in Lung Cancer - Vimarsana News

New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo's Continued Commitment in Lung Cancer

New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo's Continued Commitment in Lung Cancer will be featured as late-breaker presentation Updated TROPION-PanTumor01 results of datopotamab deruxtecan in patients with advanced NSCLC to be highlighted Biomarker analysis from phase 1 trial of patritumab deruxtecan in patients with previously treated metastatic or locally advanced EGFR mutated NSCLC to be presented Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will present new research data across its DXd ADC portfolio including ENHERTU ...